Home
HelpTest Code AFPPT Alpha-Fetoprotein (AFP), Peritoneal Fluid
Reporting Name
AFP, Peritoneal FluidUseful For
An adjunct to cytology to differentiate between malignancy-related ascites and benign causes of ascites formation
Performing Laboratory
Mayo Clinic Laboratories in Rochester
Specimen Type
PeritonealSpecimen Required
Container/Tube: Plain, plastic, screw-top tube
Specimen Volume: 2 mL
Specimen Minimum Volume
0.5 mL (Samples <0.5 mL may be rejected)
Specimen Stability Information
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Peritoneal | Frozen (preferred) | 90 days | |
| Ambient | 7 days | ||
| Refrigerated | 7 days |
Reference Values
An interpretive report will be provided.
Day(s) Performed
Monday through Saturday
Test Classification
This test has been modified from the manufacturer's instructions. Its performance characteristics were determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
86316
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| AFPPT | AFP, Peritoneal Fluid | 49761-0 |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| AFPPN | AFP, Peritoneal Fluid | 49761-0 |
| SITEF | Site | 39111-0 |
Clinical Information
Malignancy accounts for approximately 7% of cases of ascites formation. Malignant disease can cause ascites by various mechanisms including: peritoneal carcinomatosis (53%), massive liver metastasis causing portal hypertension (13%), peritoneal carcinomatosis plus massive liver metastasis (13%), hepatocellular carcinoma plus cirrhosis (7%), and chylous ascites due to lymphoma (7%). The evaluation and diagnosis of malignancy-related ascites is based on the patient clinical history, ascites fluid analysis, and imaging tests.
The overall sensitivity of cytology for the detection of malignancy-related ascites ranges from 58% to 75%. Cytology examination is most successful in patients with ascites related to peritoneal carcinomatosis as viable malignant cells are exfoliated into the ascitic fluid. However, only approximately 53% of patients with malignancy-related ascites have peritoneal carcinomatosis. Patients with other causes of malignancy-related ascites almost always have a negative cytology.
Alpha-fetoprotein (AFP) measurement in serum is used in the management of patients with hepatocellular carcinoma (HCC). Measurement of AFP in ascites fluid might be useful, when used in conjunction with cytology, in patients with a history of HCC and in whom a cause of peritoneal fluid accumulation is uncertain.
Interpretation
A peritoneal fluid alpha-fetoprotein (AFP) concentration greater than 6.0 ng/mL is suspicious but not diagnostic of ascites related to hepatocellular carcinoma (HCC). This clinical decision limit cutoff yielded a sensitivity of 58%, specificity of 96% in a study of 137 patients presenting with ascites. AFP concentrations were significantly higher in ascites caused by HCC. Ascites caused by malignancies other than HCC routinely had AFP concentrations less than 6.0 ng/mL. Therefore, negative results should be interpreted with caution.
Method Description
The instrument used is the Beckman Coulter UniCel DxI 800. The Beckman Coulter Access alpha-fetoprotein (AFP) immunoassay is a 2-site immunoenzymatic sandwich assay. A specimen is added to a reaction vessel with mouse monoclonal anti-AFP alkaline phosphatase conjugate, and paramagnetic particles coated with a second mouse monoclonal anti-AFP antibody. The AFP in the specimen binds to the immobilized monoclonal anti-AFP on the solid phase while, at the same time, the monoclonal anti-AFP-alkaline phosphatase conjugate reacts with different antigenic sites on the specimen AFP. After incubation in a reaction vessel, materials bound by the solid phase are held in a magnetic field while unbound materials are washed away. A chemiluminescent substrate is added to the reaction vessel, and light generated by the reaction is measured with a luminometer. The light production is directly proportional to the amount of AFP in the specimen. The amount of analyte in the specimen is determined by means of a stored multipoint calibration curve.(Package insert: Access AFP assay, Beckman Coulter Inc; 2020)
For all samples with AFP concentrations greater than 6 ng/mL, a dilution series is performed. A linear dilution excludes hooking and most major interferences. Samples that contain AFP concentrations less than or equal to 6 ng/mL are spiked with exogenous AFP to identify possible interferences that may cause a false-low result.
Reject Due To
| Gross hemolysis | Reject |
| Gross icterus | OK |
Method Name
Immunoenzymatic Assay
Forms
If not ordering electronically, complete, print, and send an Oncology Test Request (T729) with the specimen.